Larimar Therapeutics (LRMR) Assets Average (2014 - 2025)

Larimar Therapeutics' Assets Average history runs 12 years deep, the most recent figure standing at $166.6 million for Q4 2025.

• Quarterly Assets Average fell 20.53% year-over-year to $166.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $166.6 million (down 20.53% YoY) and the FY2025 annual result came in at $173.0 million, up 16.85% from the prior year.
• Assets Average was $166.6 million for Q4 2025 at Larimar Therapeutics, down from $168.7 million in the prior quarter.
• Across five years, Assets Average topped out at $242.7 million in Q2 2024 and bottomed at $48.9 million in Q1 2021.
• A 5-year average of $132.6 million and a median of $119.0 million in 2023 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2021 — Assets Average surged 1653.57% — and 2025, when it slumped 34.04%.
• Larimar Therapeutics' Assets Average stood at $83.3 million in 2021, then surged by 55.71% to $129.7 million in 2022, then retreated by 22.95% to $99.9 million in 2023, then jumped by 109.74% to $209.6 million in 2024, then fell by 20.53% to $166.6 million in 2025.
• Business Quant data shows LRMR's Assets Average at $166.6 million in Q4 2025, $168.7 million in Q3 2025, and $160.1 million in Q2 2025.